GlaxoSmithKline plc (ADR) (NYSE:GSK)

CAPS Rating: 4 out of 5

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Results 1 - 20 of 219 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar fartface (< 20) Submitted: 12/7/2014 7:13:51 PM : Outperform Start Price: $45.85 GSK Score: -6.22

Big Pharma and low P/E...

Recs

0
Member Avatar leaderoftheback (74.53) Submitted: 11/21/2014 4:01:14 PM : Outperform Start Price: $43.93 GSK Score: -3.10

November 21, 2014; bouncing off of two year lows. If it drops again and triggers this pick, it will probably go lower. Note to self: start accumulating.

Recs

0
Member Avatar LovinMe (46.19) Submitted: 11/12/2014 9:25:45 PM : Outperform Start Price: $45.65 GSK Score: -7.46

Div long hold.

Recs

0
Member Avatar MightyMinnow (30.45) Submitted: 10/15/2014 8:44:17 AM : Outperform Start Price: $42.56 GSK Score: -11.07

Ebola bucks

Recs

0
Member Avatar aa119634 (27.95) Submitted: 9/24/2014 12:43:14 PM : Outperform Start Price: $46.27 GSK Score: -11.52

Solid company with a history of rising dividends. PE of 13 is reasonable; stock is on sale today at prices not seen since March 2013.

Recs

0
Member Avatar asilverp (76.86) Submitted: 8/30/2014 5:08:32 PM : Outperform Start Price: $47.69 GSK Score: -13.14

I see no shortage of elderly people needing meds in the future. nice big company with a nice big dividend.

Recs

0
Member Avatar foolishlymeek (46.08) Submitted: 8/14/2014 11:06:30 PM : Outperform Start Price: $46.62 GSK Score: -13.44

Buy at the bottom!

Recs

0
Member Avatar abrodrip (< 20) Submitted: 3/27/2014 5:54:48 AM : Outperform Start Price: $51.77 GSK Score: -29.41

Whilst the failure of another cancer vaccine is undoubtedly a setback this is entirely to be expected - this proves they are investing and working on new drugs which has to be a good thing for any company. Unless GSK and other Pharmaceutical companies invest in this type of research no progress or growth will be made. GSK WILL eventually succeed in developing new drugs to treat an ageing population (not just cancer) and there WILL be massive demand for drugs.

Recs

0
Member Avatar TMFHelical (99.08) Submitted: 3/14/2014 10:00:12 AM : Outperform Start Price: $52.37 GSK Score: -30.10

Led big pharma in most drugs approved in 2013 with 5 of the ~27. Second to JNJ in approvals over the past 5 years. Solid footing.

Recs

0
Member Avatar afewgoodstocks11 (25.52) Submitted: 2/21/2014 1:46:58 PM : Outperform Start Price: $39.27 GSK Score: -38.02

Div. (Yield) $3.00 (4.4%)
Current Yield . . . . . . .7.35%

Recs

0
Member Avatar Chipperfield (63.97) Submitted: 1/23/2014 1:00:55 PM : Outperform Start Price: $51.83 GSK Score: -30.98

Drugs are promising and pay dividends. Will slightly outperform.

Recs

0
Member Avatar Coralreefer1 (26.17) Submitted: 6/29/2013 1:43:27 AM : Outperform Start Price: $46.95 GSK Score: -37.32

Biotech stocks are here to stay as one of the best areas to invest in right now.

Recs

0
Member Avatar wilkeh (42.69) Submitted: 6/6/2013 10:18:02 AM : Outperform Start Price: $47.39 GSK Score: -38.03

diversified healthcare company with good product pipeline

Recs

1
Member Avatar Teacherman333 (82.06) Submitted: 5/26/2013 1:30:25 PM : Outperform Start Price: $47.92 GSK Score: -37.63

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 51.18%
Trailing PE 19.36
PB 11.87
Div yield 4.20%

Recs

0
Member Avatar Xbeam (51.26) Submitted: 4/9/2013 3:59:35 PM : Outperform Start Price: $43.45 GSK Score: -33.62

Any kind of breaktrhough in cancer research or possible cure in HIV will make GSK success.

Recs

0
Member Avatar robotclo (72.48) Submitted: 3/19/2013 2:12:33 AM : Outperform Start Price: $41.83 GSK Score: -30.99

Good year for health care

Recs

1
Member Avatar FJW1000000 (62.44) Submitted: 2/24/2013 11:04:22 PM : Outperform Start Price: $40.86 GSK Score: -30.90

Good company with a good pipeline of drugs. Strong management team. Strong dividend payment. Good long term bet

Recs

1
Member Avatar PsychoDr (96.92) Submitted: 1/15/2013 12:05:15 PM : Outperform Start Price: $39.70 GSK Score: -33.35

Health care industry, 5.28% dividend, low dividend payout percent, history of growing dividend, pharmaceutical with a reasonable pipeline. Depressed earnings due to European crisis and a couple drugs coming off patent protection. Prognosticators are expecting flat earnings for the next two years. With a dividend reinvest position, flat earnings are fine by me. Can yo say cash cow? Share acquisition time people.

Recs

0
Member Avatar Fish08 (61.16) Submitted: 11/13/2012 2:31:07 PM : Outperform Start Price: $38.37 GSK Score: -37.84

Young avg patent life, 12 PE, 4.8% div yield.

Recs

0
Member Avatar flemmingha (52.69) Submitted: 3/24/2012 6:46:06 AM : Outperform Start Price: $39.46 GSK Score: -38.80

over 20 period moving average on a monthly chart

Featured Broker Partners


Advertisement